BBHC
CYTK icon

Brown Brothers Harriman & Co’s Cytokinetics CYTK Stock Holding History

Brown Brothers Harriman & Co’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.6K Hold
300
– – ﹤0.01% 1240
2026
Q1 		$19.8K Hold
300
– – ﹤0.01% 1233
2025
Q4 		$19.1K Buy
+300
New +$18.7K ﹤0.01% 1220
2023
Q1 		– Sell
-100
Closed -$4.58K – 1282
2022
Q4 		$4.58K Hold
100
– – ﹤0.01% 1110
2022
Q3 		$5K Hold
100
– – ﹤0.01% 1287
2022
Q2 		$4K Hold
100
– – ﹤0.01% 1167
2022
Q1 		$4K Buy
+100
New +$3.55K ﹤0.01% 1141

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown Brothers Harriman & Co's CYTK Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its Cytokinetics (CYTK) position steady in Q2 2026 at 300 shares worth $25.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1240.

Brown Brothers Harriman & Co first reported a position in CYTK in Q1 2022 and has held it in 7 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Brown Brothers Harriman & Co held 300 shares of Cytokinetics worth $25.6K as of Q2 2026.
  • Brown Brothers Harriman & Co left its Cytokinetics share count unchanged in Q2 2026.
  • Cytokinetics made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1240 holding.
  • Brown Brothers Harriman & Co first reported a position in Cytokinetics in Q1 2022 and has held it in 7 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.